Mounjaro vs Ozempic: How the two injections actually differ

Mounjaro and Ozempic come up together so often that many people assume they are two versions of one drug. They are not. Both are once-weekly diabetes injections, but they contain different molecules, come from different manufacturers, and act on the body differently.

This guide compares the two on how they work, what they are approved for, what head-to-head trials found, side effects, and cost. It also covers where a third diabetes injection, Trulicity, fits. It is educational, not medical advice. Whether either medication suits you is a decision for a licensed provider who knows your history.

Two drugs, two different molecules

Mounjaro contains tirzepatide and is made by Eli Lilly. Ozempic contains semaglutide and is made by Novo Nordisk [1, 2]. They are not interchangeable, and neither is a version of the other.

Each molecule also has a sibling brand approved for chronic weight management: Zepbound for tirzepatide and Wegovy for semaglutide. So Mounjaro vs Ozempic compares the two diabetes brands, while Zepbound vs Wegovy is the weight-management matchup. If you are weighing the two semaglutide brands against each other, see our Ozempic vs Wegovy comparison.

One recent change is worth knowing. In the US, the Ozempic name now also covers a once-daily tablet for type 2 diabetes, previously sold as Rybelsus [3]. This article focuses on the injectable pens.

Source: each product's prescribing information [1, 2, 4].

How they work: One hormone pathway or two

GLP-1 (glucagon-like peptide-1) is a hormone your gut releases after you eat. It helps the pancreas release insulin when blood sugar is high, lowers glucagon, slows stomach emptying, and acts on appetite signaling in the brain.

Semaglutide is a GLP-1 receptor agonist, meaning it activates the same receptor as the natural hormone [1]. Tirzepatide activates the GLP-1 receptor plus a second one: the receptor for GIP (glucose-dependent insulinotropic polypeptide), another gut hormone involved in insulin release [2]. That dual action is the main pharmacological difference between the two. Researchers are still studying how much each receptor contributes to tirzepatide's overall effects [5].

The doses look very different on paper. The Ozempic label starts at 0.25 mg weekly and can step up to 0.5 mg, 1 mg, and 2 mg [1]. The Mounjaro label starts at 2.5 mg weekly and rises in 2.5 mg steps, at least four weeks apart, up to 15 mg [2]. Because these are different molecules, the milligram numbers cannot be compared directly. For more on how dose increases work, see our semaglutide and tirzepatide dosing guide.

What each one is approved for

Ozempic injection is FDA-approved to improve blood sugar control in adults with type 2 diabetes, alongside diet and exercise. It is also approved to lower the risk of major cardiovascular events in adults with type 2 diabetes and heart disease. A third indication covers reducing the risk of kidney disease worsening in adults with type 2 diabetes and chronic kidney disease [1].

Mounjaro is approved to improve blood sugar control in adults with type 2 diabetes [2]. In August 2026, the FDA added a second indication: lowering the risk of major cardiovascular events in adults with type 2 diabetes at high risk [6].

Neither Mounjaro nor Ozempic is FDA-approved for weight management. The weight-management approvals belong to Zepbound and Wegovy. Using Mounjaro or Ozempic for weight loss outside their approvals is off-label, and only a provider can decide whether that is appropriate.

Mounjaro vs Ozempic for weight loss: What the trials show

The closest comparison is SURPASS-2, a 40-week randomized trial in 1,878 adults with type 2 diabetes who were already taking metformin [7]. Participants received tirzepatide at 5 mg, 10 mg, or 15 mg, or semaglutide at 1 mg. Average weight loss at 40 weeks was [7]:

• Tirzepatide 5 mg: 7.6 kg (about 17 lb)
• Tirzepatide 10 mg: 9.3 kg (about 20 lb)
• Tirzepatide 15 mg: 11.2 kg (about 25 lb)
• Semaglutide 1 mg: 5.7 kg (about 13 lb)

Between 34% and 57% of people on tirzepatide lost at least 10% of their body weight, compared with 24% on semaglutide [7].

One caveat matters here. SURPASS-2 tested semaglutide at 1 mg, but the Ozempic label now goes up to 2 mg, a dose that trial did not include [1, 7].

A second head-to-head trial, SURMOUNT-5, enrolled 751 adults with obesity but without diabetes [8]. It used the weight-management brands, Zepbound and Wegovy, at the highest dose each person tolerated. At 72 weeks, average weight change was 20.2% with tirzepatide and 13.7% with semaglutide [8].

So in both trials, tirzepatide produced more average weight loss than semaglutide at the doses studied. These are group averages from controlled trials, and some participants lost far more or far less. Results vary and depend on the individual and the treating provider.

Side effects compared

The two medications have overlapping safety profiles, although their prescribing information is not identical. Both labels carry a boxed warning about thyroid C-cell tumors seen in rodents. Both are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) [1, 2].

Digestive side effects are the most common for both. In SURPASS-2, reported rates were [7]:

• Nausea: 17% to 22% with tirzepatide, 18% with semaglutide
• Diarrhea: 13% to 16% with tirzepatide, 12% with semaglutide
• Vomiting: 6% to 10% with tirzepatide, 8% with semaglutide

Most of these events were mild to moderate [7].

Both labels also warn about pancreatitis, gallbladder problems, and low blood sugar when combined with insulin or a sulfonylurea. Other shared warnings include kidney injury linked to dehydration, serious allergic reactions, diabetic retinopathy complications, and aspiration risk during anesthesia or deep sedation [1, 2]. The Mounjaro label also notes it can make oral birth control less effective. It advises a non-oral or backup method for four weeks after starting and after each dose increase [2].

Like any prescription medication, both carry risks and possible side effects your provider will review with you. These are not comprehensive lists of risks or contraindications; patients should review the prescribing information and discuss their medical history with their clinician.

And where does Trulicity fit?

For anyone comparing Trulicity vs Ozempic vs Mounjaro, the third drug is dulaglutide, a once-weekly GLP-1 receptor agonist made by Eli Lilly [4]. Like Ozempic, Trulicity is approved for type 2 diabetes and to reduce the risk of major cardiovascular events in certain adults with the condition. Its labeled doses run from 0.75 mg to 4.5 mg [4].

Trulicity has been tested head to head against both drugs:

• Against Ozempic (SUSTAIN 7): over 40 weeks, average weight loss was 4.6 kg with semaglutide 0.5 mg versus 2.3 kg with dulaglutide 0.75 mg. At the higher doses tested, it was 6.5 kg with semaglutide 1 mg versus 3.0 kg with dulaglutide 1.5 mg [9].
• Against Mounjaro (SURPASS-CVOT): in 13,299 adults with type 2 diabetes and cardiovascular disease, tirzepatide was noninferior to dulaglutide for major cardiovascular events [10]. Average weight change was about 11.6% with tirzepatide versus 4.5% with dulaglutide [10].

SUSTAIN 7 did not test the 3 mg and 4.5 mg Trulicity doses that were approved later [4, 9]. Even so, in these studies dulaglutide produced less weight loss than either semaglutide or tirzepatide. That does not make it the wrong choice for everyone. A provider may still consider it based on your history, how you tolerated other medications, or what your plan covers.

Cost and savings programs

Prices change often, so treat these figures as approximate and check the manufacturer's site for current terms. These are manufacturer prices, not Luvo prices.

• Mounjaro: the list price is about $1,112 for a month's supply [11]. Lilly offers a savings card for people with commercial insurance and also sells Mounjaro directly at a self-pay price starting at $499 a month [11].
• Ozempic: the list price is roughly $1,000 a month [12]. Through NovoCare Pharmacy, people new to the offer pay $199 a month for their first two fills of the 0.25 mg or 0.5 mg pen [13]. That offer runs through December 31, 2026. After those two fills, the price renews at $349 a month for the 0.25 mg, 0.5 mg, or 1 mg pen. The 2 mg pen is $499 a month [13]. Eligibility restrictions apply, and government beneficiaries are excluded [13].

Insurance coverage often matters more than list price. Coverage varies by plan. Because Mounjaro and Ozempic have FDA-approved type 2 diabetes indications, insurers may require documentation of type 2 diabetes, prior authorization, step therapy, or other clinical criteria before providing coverage.

Compounded semaglutide and tirzepatide

Compounded semaglutide and tirzepatide products are not FDA-approved and do not undergo FDA review for safety, effectiveness, or quality before they are marketed [14]. FDA recommends that compounded drugs be used only when a patient's medical needs cannot be met by an available FDA-approved drug. Federal and state laws also restrict when commercially available medications may be compounded. A compounded product should not be considered a generic or FDA-approved equivalent of Ozempic, Mounjaro, Wegovy, or Zepbound. Whether compounding is clinically appropriate and legally permissible depends on the individual patient and applicable compounding requirements. Data from clinical trials of Ozempic and Mounjaro should not be assumed to establish the safety, effectiveness, quality, potency, or bioequivalence of a compounded product.

The rules for compounded GLP-1 medications have been changing, so what is available can shift. A provider can explain the current options and their risks. For more, read the important safety information for compounded semaglutide and for compounded tirzepatide.

How a provider decides

There is no single right answer in the Ozempic vs Mounjaro choice. A provider typically weighs:

• Whether you have type 2 diabetes, which affects both the approved use and insurance coverage
• Any heart or kidney disease, since the labels carry different outcome indications
• Personal or family history of medullary thyroid carcinoma or MEN 2, plus any history of pancreatitis or gallbladder disease
• Other medications, including insulin, sulfonylureas, and oral birth control
• How you tolerated any GLP-1 medication in the past
• Cost, coverage, and whether a weekly pen or a daily tablet suits you better

Common questions

Which works better for weight loss, Mounjaro or Ozempic?
In head-to-head trials, tirzepatide produced more average weight loss than semaglutide at the doses tested, including in SURPASS-2 and SURMOUNT-5 [7, 8]. Those are group averages. Individual results vary, and a trial average does not predict how any one person will respond.

Can I switch from Ozempic to Mounjaro?
There is no FDA-labeled milligram-for-milligram conversion between semaglutide and tirzepatide. Mounjaro's labeled initiation dose is 2.5 mg once weekly [2], but a clinician should determine the appropriate transition plan based on the patient's current medication, dose, tolerability, glycemic control, and other clinical factors.

Are the side effects different?
They are broadly similar. Both most often cause nausea, diarrhea, and vomiting, at comparable rates in SURPASS-2 [7], and both carry the same boxed warning [1, 2]. One practical difference is Mounjaro's effect on oral birth control, which your provider should discuss with you [2].

Why would insurance cover one and not the other?
Two drugs with similar clinical uses may have different formulary placement because of a plan's benefit design, formulary decisions, utilization-management requirements, and contracting arrangements.

Next steps

If any of this sounds like what you are dealing with, the next step is a conversation with a licensed provider who can review your history and decide whether treatment makes sense for you. Nothing is prescribed or shipped without that review. Any medication preference you indicate is only a starting point for discussion. A licensed clinician independently determines whether prescription treatment is medically appropriate and, if so, which medication, dose, and treatment plan are appropriate based on your clinical evaluation.

Explore Luvo's Weight Loss Program.